$1.12
32.39% day before yesterday
Nasdaq, Dec 27, 09:50 pm CET
ISIN
US29970R1059
Symbol
EVAX
Sector
Industry

Evaxion Biotech A/S - ADR Stock price

$1.06
-0.51 32.48% 1M
-1.81 63.07% 6M
-5.80 84.54% YTD
-5.94 84.86% 1Y
-43.34 97.61% 3Y
-8.94 89.40% 5Y
-8.94 89.40% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.21 25.30%
ISIN
US29970R1059
Symbol
EVAX
Sector
Industry

Key metrics

Market capitalization $5.74m
Enterprise Value $8.24m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 29.43
P/S ratio (TTM) P/S ratio 20.50
P/B ratio (TTM) P/B ratio 4.58
Revenue (TTM) Revenue $280.00k
EBIT (operating result TTM) EBIT $-19.09m
Cash position $4.58m
EPS (TTM) EPS $-4.60
P/S forward 1.28
EV/Sales forward 1.84
Short interest 1.32%
Show more

Is Evaxion Biotech A/S - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Evaxion Biotech A/S - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:

Buy
100%

Financial data from Evaxion Biotech A/S - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.28 0.28
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.66 8.66
11% 11%
3,093%
- Research and Development Expense 11 11
28% 28%
3,825%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -19 -19
23% 23%
-6,819%
Net Profit -15 -15
38% 38%
-5,432%

In millions USD.

Don't miss a Thing! We will send you all news about Evaxion Biotech A/S - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evaxion Biotech A/S - ADR Stock News

Neutral
GlobeNewsWire
about 2 months ago
COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new positive preclinical data from its ongoing cytomegalovirus (CMV) vaccine program named EVX-V1. The data will be presented today at the 9th International Conference on Vaccines Research & Development, t...
Neutral
GlobeNewsWire
about 2 months ago
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results.
Neutral
GlobeNewsWire
2 months ago
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.
More Evaxion Biotech A/S - ADR News

Company Profile

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on 11 August, 2008 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Christian Kanstrup
Employees 49
Founded 2008
Website www.evaxion-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today